LY3200882 + Pembrolizumab
Phase 1/2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer
Trial Timeline
Dec 5, 2019 → May 11, 2023
NCT ID
NCT04158700About LY3200882 + Pembrolizumab
LY3200882 + Pembrolizumab is a phase 1/2 stage product being developed by Eli Lilly for Advanced Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04158700. Target conditions include Advanced Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04158700 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Advanced Cancer